Ipriflavone is made from the soy isoflavone Daidzein. It is used in the treatment of osteoporosis.
Other names for Ipriflavone include: IP.
Ask your doctor, nurse, or pharmacist if you need more information about this medicine or if any information in this leaflet concerns you.
Tell your doctor if you
Talk with your caregiver about how much Ipriflavone you should take. The amount depends on the strength of the medicine and the reason you are taking Ipriflavone. If you are using this medicine without instructions from your caregiver, follow the directions on the medicine bottle. Do not take more medicine or take it more often than the directions tell you to.
Keep all medicine locked up and away from children. Store medicine away from heat and direct light. Do not store your medicine in the bathroom, near the kitchen sink, or in other damp places. Heat or moisture may cause the medicine to break down and not work the way it should work. Throw away medicine that is out of date or that you do not need. Never share your medicine with others.
Do not take Ipriflavone without talking to your doctor first if you are taking:
Stop taking your medicine right away and talk to your doctor if you have any of the following side effects. Your medicine may be causing these symptoms which may mean you are allergic to it.
This medicine may also cause other side effects. Tell your doctor if you have side effects that you think are caused by this medicine.
1. Murray M & Pizzorno ND: Encyclopedia of Natural Medicine (2nd ed). Prima Press, Rocklin, CA; 1998.
2. Brandi ML: new treatment strategies: Ipriflavone, Strontium, Vitamin D Metabolites and Analogs. Am J Med 1993; 95(Suppl.5A): 69S-74S.
3. Moscarini M,Patacchiola F, Spacca G et al: New Perspective in the treatment of Postmenopausal Osteoporosis - Ipriflavone. Gynecol Endocrinol 1994; 8:203-207.
4. Passeri M, Biondi M, Costi D et al: Effect of ipriflavone on bone mass in elderly osteoporotic women. Bone Miner 1992;19(supp1):S57-S62.
5. Agnusdei D, Crepaldi G, Isaia et al: A double blind placebo-controlled trial of Ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int 1997;61:142-147.
6. Agnusdei D, Zacchei F, Bigazzi S et al: Metabolic and clinical effects of ipriflavone in established postmenopausal osteoporosis. Drugs Exp Clin Res 1989; 15(2):97-104.
7. Takahashi J, Kawakatsu K, Wakayama T et al: Elevation of serum theophylline levels by ipriflavone in a patient with chronic obstructive pulmonary disease. Eur J Clin Pharmacol 1992; 43:207-208.
8. Shino M: Pharmacokinetic study of ipriflavone by oral administration in healthy male volunteers. Jpn Pharmacol Ther 1985; 13:235.
9. Ju YH, Doerge DR, Allred KF et al: Dietary genestein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002; 62(9):2474-2477.